Rochester, NY (PRWEB) December 12, 2012
Today, iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, announced that the company doubled its fiscal first quarter revenues for the period ending September 30th, 2012. The new customer growth reflects iCardiac’s innovation around improving the precision of key cardiac safety measurements. This same innovation was recently recognized by local government officials as part of their promotion of more innovation nationally. This recognition follows iCardiac’s honor of being listed on the Science Coalition 100 of the nation’s 100 great technology transfer success stories and also as one of the fastest growing companies in Rochester, NY as determined by the Democrat & Chronicle.
“These honors, both locally and nationally, reflect iCardiac’s robust growth, which is tied to our solid commitment to client satisfaction in cardiac safety analysis,” said Mikael Totterman, chief executive officer of iCardiac. “Our team is growing and our company is poised for continued growth in 2013.”
iCardiac Technologies now serves 7 of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.
iCardiac Technologies is a global cardiac safety company that has commercialized advanced research originating at leading academic institutions and pharmaceutical companies. Its reach is international, working with pharmaceutical and medical device clients all over the world to bring the best results to cardiac safety. For more information visit: http://www.icardiac.com/.